Overview
We're starting the new year strong with our first event in the Meet With Venture Capital series! Meet with Angelini Ventures, the venture capital firm of Angelini Industries. Angelini Ventures invests EUR€300,000,000 globally in biotech and life sciences companies, with a focus on leveraging technology to improve healthcare, reshape patient journeys, and address unmet needs in vulnerable populations.
Join us in-person to learn more about Angelini Ventures through an insightful presentation and a dedicated Q&A session!
As capacity is limited, please register for the waitlist. You'll receive an email if your spot is confirmed. Thank you for your patience and understanding.
Photography and videography will be captured during this event. Through your participation, you are granting Johnson & Johnson Innovation - JLABS consent to utilize these images and videos for promotional purposes, which may include social media, website and publication purposes. If you do not wish to be photographed, kindly inform the photographer at the event.
Schedule
Date: 09 Jan 2025, Thursday
Time: 3:30 PM - 6:00 PM (GMT +8:00) Kuala Lumpur, Singapore
Location: Guoco Midtown Network Hub, Level 2, 126 Beach Road, Singapore 189772
Speakers
Speaker's Profile:
Paolo Di Giorgio, CEO & Managing Director, Angelini Ventures
Paolo is the Chief Executive Officer and Managing Director of Angelini Ventures, a €300M corporate fund investing in biotech, digital health and medtech on a global scale. He is currently a board member of Argobio and Extend, an observer board member of Pretzel Therapeutics, GenEp, Nouscom and Arclight Therapeutics, and a member of the investment committee of the Angelini Lumira Bioscience Fund. Paolo is a life sciences executive with over 20 years of experience in venture capital, R&D, external innovation, and business development. Since 2016, he was the Head of R&D at Angelini Pharma, where he led their pre-clinical development group with multiple programs in the areas of CNS and anti-infectives. In 2019 he created and led the external innovation and corporate venturing units (Angelini Pharma Ventures) of Angelini Pharma.
Speaker's Profile:
Elia Stupka, Managing Director, Angelini Ventures
Elia is a founding Managing Director at Angelini Ventures, bringing over 20 years of executive experience in healthcare and life sciences across industry, academic, and clinical settings. He previously served on the leadership team of Health Catalyst through their NASDAQ IPO in 2019, following roles as Senior Director of Data Science at Dana-Farber Cancer Institute and Venture Partner at First Star Ventures. Before his work in the United States, he was a Director at Boehringer Ingelheim Pharma in Germany. Prior to his industry career, Elia was a leading academic scientist in the genomics field internationally. He began his career as a member of the first team that annotated the human genome in Cambridge, U.K. (1999-2001). He then collaborated with Nobel Laureate Sydney Brenner to build Asia's first genome project (Fugu genome).
